Good morning, everyone, and thank you for joining the EDIT-301 Clinical Update webinar. This webinar is being recorded and can be accessed in the future through this same link or through the investor section of the company's website. After the webinar, the call will be open to Q&A. To ask a question, please click the Raise Hand feature in the webinar portal. As a reminder, various remarks that we make during this presentation about the company's future expectations, plans, and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC, as updated by our subsequent filings. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. This webinar will be presented by Editas Medicine's CEO, Gilmore O'Neill, and our Chief Medical Officer, Baisong Mei. I'd now like to turn the call over to Gilmore for opening comments. Thanks, Cristi. Good morning, and thank you for joining us for this webinar presentation of our accumulated clinical experience with EDIT-301. I'm excited to be here today to share additional clinical data from the RUBY and EdiTHAL studies of EDIT-301. I joined Editas 18 months ago because I saw a huge opportunity to help transform Editas from a development-stage technology platform company into a commercial-stage genome editing company. And we are well on our way, driving towards commercialization with our deliberately designed management team, our focused strategy, and our groundbreaking science. In the past 18 months, we have formed a new senior management team with a proven track record of drug approvals and with strong domain expertise to leverage cutting-edge gene editing technology. We have focused our strategy on lead asset EDIT-301 and the development of in vivo medicines, making investments based on high-conviction targets with a high probability of technical, regulatory, and commercial success. Finally, we have increased our business development activities, specifically out-licensing our foundational Cas9 intellectual property, and we have a strong cash position to fund these activities. Finally, I am pleased to share EDIT-301 is now known as reni-cel (renizgamglogene autogedtemcel) or reni-cel. Now, since the June 2023 data disclosure at the European Hematology Association EHA conference and in our company-sponsored webcast, we have shared that we would want to continue to see rapid correction of anemia to normal physiological hemoglobin levels and fetal hemoglobin levels in excess of 40% that are well above the sickle threshold, and a safety profile that is consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant, and all treated sickle cell patients free of vaso-occlusive events or VOEs, and all TDT patients achieving transfusion independence. Before I hand over to Baisong to take you through the data, I want to share a few key takeaways from today's webinar. Reni-cel drives early, robust correction of anemia to a normal physiological range, total hemoglobin in sickle cell disease patients. reni-cel drives robust, sustained increases in fetal hemoglobin in excess of 40%. All RUBY sickle cell patients have remained free of vaso-occlusive events following reni-cel treatment. reni-cel-treated sickle cell and transfusion-dependent thalassemia patients have shown successful engraftment and have stopped RBC or red cell transfusions. The safety profile of reni-cel observed to date is consistent with myeloablative conditioning of busulfan and autologous hematopoietic stem cell transplant. In addition, the trajectory of the correction of anemia and expression of fetal hemoglobin are consistent across reni-cel-treated sickle cell disease and beta thalassemia patients at the same follow-up time. These new data reinforce our belief that we have competitive product and indeed a product differentiated from other treatments, thanks to its deliberate design by rapid correction anemia. But what is the impact of these hematological outcomes on a patient? I would like to share a quote from a RUBY trial participant, a 26-year-old man who shared his experiences with us since dosing. I just want to highlight this particular quote: "Before, I had to work so hard at everything. I was a dreamer. Now I can do anything. I feel like myself again." I thank this patient and trial participant for sharing his story of how reni-cel has helped him pursue his dreams. I'd like to thank all patients and trial participants, their families, investigators, study site staff members, our CRO partners, employees, shareholders, and you as we follow this journey to bring potent new gene editing medicines to market. Baisong will now take you through the RUBY and EDIT-301 study and share the data to support these findings. Thanks, Gilmore. Sickle cell disease is an inherited, life-threatening hematological disorder, which starts to cause serious complications in early childhood. ... This disorder affects millions of people worldwide, including approximately 100,000 people in the United States. Sickle cell disease can result in severe anemia and sickling-induced blood vessel blockage, resulting in unpredictable and severe attacks of acute pain, stroke, acute chest syndrome, liver disease, renal failure, and shortened lifespan. With limited approved treatment options, there are significant unmet medical needs for sickle cell patients. Natural genetic variants in the gamma globin promoter can cause hereditary persistence of fetal hemoglobin, HPFH, with high levels of fetal hemoglobin in red blood cells. In sickle cell patients who co-inherit hereditary persistence of fetal hemoglobin, the patient can have reduction or absence of sickle cell symptoms. Levels greater than 30% fetal hemoglobin are associated with significant reduction or absence of sickle cell symptoms, particularly vaso-occlusive events. In addition, the amount of total hemoglobin within an individual red blood cell is important. That is called cellular fetal hemoglobin levels. When cellular fetal hemoglobin levels exceed 10 pg/cell, it is considered clinically meaningful because it prevents that red blood cell from sickling. Therefore, based on this natural occurrence, we believe that increased fetal hemoglobin expression will ameliorate the symptoms and complications of sickle cell disease. The choice of CRISPR enzyme and the target for editing to switch on fetal hemoglobin expression matter. Before Editas selected the HBG1/2 promoter as our genomic target for upregulation of fetal hemoglobin, we conducted a comprehensive preclinical study for head-to-head comparison between editing of HBG1/2 promoter versus editing of BCL11A. HBG1/2 editing in human CD34+ cells result in greater red blood cell production, normal proliferative capacity, and improved red blood cell health when compared to editing of BCL11A. AsCas12a is our proprietary, high-fidelity, high-specificity CRISPR nuclease and is very different from Cas9 enzyme used by others. AsCas12a has demonstrated superior characteristics that increase the efficiency of editing and significantly reduce off-target editing when compared to other CRISPR nucleases, including Cas9. Additionally, our comprehensive off-targeting assessment used multiple orthogonal methods, including in silico, biochemical, and cellular, followed by verification of candidate sites. This approach, in combination with high specificity AsCas12a enzyme, gave us confidence in the design of reni-cel to provide high editing efficiency and no off-target editing. Therefore, using AsCas12a to edit HBG1/2 promoter should deliver our desired drug attributes of correction of anemia by increasing and normalizing total hemoglobin and more sustained expression of fetal hemoglobin. The RUBY trial has been designed as a registrational study to evaluate the efficacy, safety, and tolerability of reni-cel for treatment of severe sickle cell disease. The reni-cel trial will recruit approximately 40 patients with severe sickle cell disease and have a history of at least 2 severe vaso-occlusive events per year for the 2 years prior to enrollment. In addition to safety and resolution of vaso-occlusive events up... reni-cel continues to show a favorable safety profile, and the reni-cel was well tolerated by the 11 patients dosed in the RUBY trial. All 11 patients are homozygous severe sickle cell disease, and during the 2-year prior to enrollment to RUBY trial, patients had a mean annual rate of severe vaso-occlusive events of 3.9. The mean follow-up period post reni-cel treatment was 6.5 months. The first 2 patients have had 18 and 15 months follow-up period, respectively. All 10 patients with greater than 1 month follow-up period had successful neutrophil and platelet engraftment after reni-cel infusion. The neutrophil engraftment within 1 month and platelet engraftment within 1.5 months. To date, the safety profile has been consistent with that of myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. No serious adverse events related to reni-cel treatment were reported after reni-cel infusion. Importantly, all treated RUBY patients are VOE-free since reni-cel infusion. This slide shows the data from 10 patients with over 1 month follow-up period. Their VOE during the 2 years before enrolling to RUBY trial versus VOE after the reni-cel infusion. While the patients have frequent VOEs before the trial, there are no VOE after reni-cel treatment. This past June, we showed that patient 1 and 2 from the RUBY trial had a normal physiological level of total hemoglobin by month 5 after treatment, and the fetal hemoglobin level greater than 40%. As a reminder, fetal hemoglobin level exceeding 30% is considered clinically meaningful reduction or elimination of sickle cell symptoms, particularly vaso-occlusive event. Here we show data from more patients and a longer follow-up period, up to 18 months. The data reaffirms our confidence that this effect is durable. Let me take you through the data. The X-axis represents the follow-up time after infusion of reni-cel. The Y-axis represent the mean total hemoglobin level, and the total hemoglobin value are denoted on top of the bars. The mean total hemoglobin level ranged from 15.1-16.9 grams per deciliter, 5 months after reni-cel infusion. All 6 RUBY patients who had 5 months or longer follow-up period had a normal total hemoglobin level since month 5, and maintained the physiological level of total hemoglobin during the follow-up period up to 18 months. For reference, the normal total hemoglobin is 13.6-18 grams per deciliter for men, and 12-16 grams per deciliter for women. It's marked by gray bars running across the top of the graphs. I mentioned total hemoglobin level at month 5 because at this time, the transfused blood has been washed out, so that the total hemoglobin level at month 5 is not confounded by transfused blood. The fetal hemoglobin fraction is represented at the bottom of the bar in orange. The fetal hemoglobin level of all patients reached greater, greater than 40% in month 4 after reni-cel infusion, and maintained greater than, greater than 40% during the follow-up period, up to 18 months. The clinical data thus far reaffirm our belief that achieving sustained normal level of total hemoglobin could be a potential point of differentiation for reni-cel. Moving to transfusion-dependent beta thalassemia, or TDT. TDT is characterized by severe anemia, hemolysis, severe ineffective erythropoiesis. Clinical manifestations appear in infancy, and patients require lifelong regular transfusions for survival. Similar to sickle cell disease, increased fetal hemoglobin levels can also ameliorate the manifestations of TDT and reduce or correct anemia. The EDDYCEL study has been designed to evaluate the safety, tolerability, and efficacy of reni-cel for treatment of TDT. The EDDYCEL's patients experience with reni-cel to date resembles that of the RUBY patients in increase of total hemoglobin and the fetal hemoglobin. This past June, we shared early data from the first patient with 1.5 months follow-up after reni-cel infusion. Today, I'm pleased to share a dataset of six EDDYCEL patients. These patients had 1-8 months follow-up post reni-cel infusion, with four patients being at least 3 months post reni-cel infusion. reni-cel patients treated with the reni-cel has demonstrated successful neutrophil and platelet engraftment, and the safety profile has been consistent with that of myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. Following reni-cel infusion, mean total hemoglobin level increased to 13.1 gram per deciliter by month 5, and maintained over the follow-up period up to 8 months post reni-cel infusion, well above transfusion independence threshold. As a reminder, average total hemoglobin level at or above 9 gram per deciliter is considered transfusion-independent for TDT patients. The increased total hemoglobin level is driven by rapid and robust increase of fetal hemoglobin expression. After reni-cel infusion, the mean fetal hemoglobin level rapidly increased to 9.4 gram per deciliter at month 4, remained high over the follow-up period. Excitingly, this data showed that total hemoglobin and the fetal hemoglobin increased, a trajectory seen in RUBY patients at the same time point. In summary, this data reconfirmed our initial clinical results shared in June. reni-cel drives early, robust correction of anemia to a normal physiological range of total hemoglobin in sickle cell patients. reni-cel drives robust, sustained increase in fetal hemoglobin in excess of 40%. All RUBY sickle cell patients had remained free of vaso-occlusive events following reni-cel treatment. reni-cel-treated sickle cell and beta thalassemia patient have shown successful engraftment, have stopped red blood cell transfusion. And the safety profile of reni-cel observed to date is consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. In addition, the trajectory of correction anemia and expression of fetal hemoglobin is consistent across the reni-cel-treated sickle cell disease and beta thalassemia patients at the same follow-up time points. Both RUBY and EDDYCEL trials have strong, positive momentum. We look forward to sharing more data from more patients and longer observation of both RUBY and EDDYCEL studies in mid 2024. Finally, I thank all patients, their family, investigators, Vericel staff members, our CRO partners, employees, shareholders, and you- ... as we're following this journey to bring potent new gene editing machine medicines to market. Now I turn the call back to our CEO, Gilmore. Thank you, Baisong. As you can see, these data give us even more confidence that reni-cel has the potential to be a competitive product and a potentially differentiated medicine that can give robust clinical benefit to patients with severe sickle cell disease and beta thalassemia. In closing, clinical execution and the path to commercialization for reni-cel are top priorities for us. We are on track to achieve our goal of dosing the 20th RUBY patient in the January timeframe, and we remain on track to present a substantial clinical data set of sickle cell patients in mid-2024. On the regulatory front, we are also pleased that the FDA granted RMAT designation to reni-cel for the treatment of severe sickle cell disease in October. To further enable commercialization on the manufacturing front, we've ensured our ability to scale reni-cel manufacturing, both for clinical trial supply as well as ensure commercial readiness. We remain confident that reni-cel has the potential to be not just a competitive product, but a differentiated medicine that can give robust clinical benefit to patients with severe sickle cell disease and beta thalassemia, and has the potential for clinical differentiation in the long term. We are well-positioned to drive reni-cel to regulatory file approval. Thank you very much for your interest in Editas, and we are happy now to answer questions. Thank you. We will now begin the Q&A session. As a reminder, please select the Raise Hand feature at the bottom of the Zoom interface to be placed in the virtual queue. We will call on you and ask you to unmute yourself. Our first question comes from Jack Allen from Baird. Your line is open, feel free to unmute. Hi, thank you. Can you guys hear me? Yes, Jack, we can. Thank you. Awesome. Congratulations- And just... Yeah, go, go ahead. Yeah, let me know if you can't hear me. But congratulations on the data. Very interesting data set here. I guess maybe one question I had was around the thoughts on total hemoglobin as it relates to remaining within the normal range for the given genders. I know that some of these patients have different normal ranges, depending on if they're male or female. Are you seeing that all the patients are remaining in their normal range? And if not, is there any risk to overexpression of total hemoglobin? And then I have a quick follow-up as well, if I may. Thanks very much, Jack, for your question. I will warn you that owing to the ASH, we're in different sites, and so I will be, how should I say, overseeing or facilitating questions, but I'm going to pass this question to Baisong, my... Our Chief Medical Officer. Yeah. Thank you, Gilmore. Hey, thanks, Jack. Thank you for your question. So as I mentioned, at month 5, we have 6 patients, which month 5 or longer, and all those patients are in a different gender. They are in within the normal range of their specific reference range. Got it. Great, and then just a brief follow-up- Yeah, we have- Uh, yep. Sorry, go ahead. You had another question about overexpression. I just wanted to follow up on that. No, we do not have a concern about overexpression on these patients. Got it. Great. And then, just a brief follow-up. I know it's a very exciting time in the CRISPR cell therapy space. I'm sure you guys have seen the recent approvals. I was wondering if you had any overarching remarks as it relates to the approvals. And I know there are some IP dynamics as it relates to CRISPR-Cas9 and products in the US. I'd love to hear any thoughts you have as it relates to these updates. Yeah, definitely, Jack, we'd be delighted to. Listen, we share the excitement of everybody involved. This is a fantastic moment in time, most particularly for sickle cell warriors. But it's also a very exciting time for programmed genome editing, and more specifically, using CRISPR based technologies, with a significant step with this first approval of a CRISPR based medicine. Frankly, you know, it validates our own approach to approval and differentiation in this context. And then, with regard to the IP situation, you know, we have consistently expressed our desire and interest to sublicense our Cas9 technology to enable these medicines and their approvals. Now, we talk to many companies about Cas9 licenses, but we do not discuss any specific conversations until, you know, there is a signed agreement. Got it. Great! Well, congratulations again on the progress, and a very exciting time in this space. Thank you very much, Jack. Our next question comes from Gina Wang from Barclays. Thank you. I have three quick questions. The first one, a little bit, first two are a little bit technical questions. First one is regarding the cell collections for sickle cells. What is the average cycles you need to do in order to collect sufficient cells for sickle cell disease program? And the second question is regarding the fetal globin. What is the sweet spot regarding the percentage of the fetal globin? Will over 60, 100%, sorry, 60%, would that be too high or any concern, safety concern there? And then lastly, very quickly, I just wanted to ask, you know, after recent approvals for Leqembi and the Casgevy last Friday, any update or thoughts on regulatory path? ... Yes, thank you very much, Gina. So, with regard to the cell collections, I'm going to pass that question to Baisong, and then I'll facilitate the other two questions. So, Baisong, just the average number of cycles for cell collections. Yeah. So we are very happy with our cell selection cycle. We actually have a specific optimization for the apheresis process and have on-site support for the apheresis in the study site. We are doing very well, but we have not shared the specific average cycle publicly on that, but we are doing very well and very happy to see the results. With regard to the fetal hemoglobin question you asked, Gina, around the sweet spot, and is there a level that is too high? You know, I'm gonna ask Baisong to address that. Of course, in many ways you can actually look to the co-inheritance of hereditary persistence of fetal hemoglobin, particularly in the context of thalassemia, where you see very high percentages without apparent, with actually with benefit and without apparent adverse effect. Baisong, if you want to build on that. Yeah, yeah, thank you, Cameron. Yeah. So Gina, yeah, that's certainly, you know, a very interesting question because you wanna see the sickle cell and thalassemia doing differently. So for sickle cell patient, really is you're trying to prevent a sickling with the increased amount of fetal hemoglobin. So the knowledge we have so far is primarily based on two things before. One is hereditary persistence of fetal hemoglobin, and the other one is related to the hydroxyurea. But now, of course, we have data from, you know, our study as well. Our other study-wise, we have better understanding. So certainly that there is a positive correlation, that 20% you start to see the impact and 30% you have a better one, but now we actually see, 40% really give good results. Then we are further to see, exactly as you said, whether 60% is necessary or not, or whether it's benefit as well, what remain to be seen. But we are happy to see that, the higher fetal hemoglobin level give us better benefit this point. Thanks very much, Baisong. Then, Gina, your third question is around any updates or, you know, on the regulatory pathway. We're thinking about post these critical approvals. Indeed, we see this approval as a validation of our strategy. As Baisong said, we continue to enroll. We are on track to really be in a position with that good momentum on dosing and recruitment, to present a substantial data set in the middle of 2024. And benchmarking by the original exa-cel BLA accepted by the FDA, including their original efficacy data set of 20 patients with 16 months follow-up. You know, we believe this validates a line of sight to a BLA in 2025. and it's just probably worth reminding as well that the FDA granted us RMAT in October, you know, even while they were reviewing the exa-cel data set, you know, really confirming, you know, a remaining unmet need per the regulation that oversees RMAT granting. And obviously, that was based on their review of our current clinical data at the time. So again, with that view, with also the RMAT granting us opportunities or increased amount of opportunities to engage with senior FDA officials, it further increases our confidence in a timely review. Thank you very much. Thank you. Our next question comes from June Li from Truist. Your line is open, June Li. Feel free to unmute. Hi, yes. Thank you, and congrats on the very strong data. In the press release, you see that the reni-cel can be clinically differentiated. Can you point to a specific data point supporting this? And can you share some specifics on how editing the promoter differs from enhancer in terms of mimicking the hereditary persistence of fetal hemoglobin? One of the slides actually had a list of things that were better with promoter editing versus the enhancer editing. I'm just really curious what you're referring to. Thank you. Yes, thanks very much, June. With regards to the clinical differentiation, beyond the hematologic parameters we have presented today, let me pass the question to Baisong to talk about, you know, how our clinical trial is designed. Baisong. Yeah. Thanks. Thank you. I think when we clinically study these, the EDIT-301 and reni-cel in the sickle cell patient, we're looking into three categories of endpoints to form the potential differentiation. As I mentioned earlier, that the normalization or correction with the anemia could be a potential differentiation point. And with that in mind, we are looking, of course, for hematological parameters to see the difference in there. But more importantly, we're looking to see the end organ function after the advent of treatment from cardiovascular, pulmonary, liver, renal functions, too. Another important category we're looking into that is patient-reported outcome, because that anemia can really impact patient's quality of life, right? So we all know that when we go to high altitude, we have short breaks. So that's kind of the indication, shortage of oxygen in our system, and which is to relate to anemia. And also end organ function, the literature already in the meta-analysis says, for the sickle cell patients, that level of total hemoglobin is related to the end organ functions. So that's kind of directions we're looking to that for the differentiation perspective. ... Great. Thanks very much, Baisong. And then, June, you asked us just about how our targeting the, the gamma-globin promoter directly, as opposed to the BCL11A suppressor, might differentiate. Well, I think the key thing beyond just the clinical data is that our non-clinical data showed in a head-to-head comparison that targeting the gamma-globin promoter as opposed to the BCL11A suppressor would actually result in, and did indeed result in, increased red cell output, longevity, and health in a non-clinical model. We presented those data a few years ago. Obviously, one can speculate about the underlying mechanism beyond the empiric observation. Yet one possibility is that directly targeting a single suppressor, you know, may have less effect, impact than targeting the promoter itself, where you can actually essentially interdict or interfere with both trans as well as cis elements that might impact the promoter and its impact on downstream expression. Thank you so much, and congrats on the data again. Thank you. Our next question comes from Samantha Semenkow from Citi. Hi, thanks very much for taking the question, and congrats on the data, as well. So, you know, at ASH, there's just been a lot of discussion on how to ensure sickle cell disease patients are able to access these gene-editing therapies, you know, following the recent approvals. The conversation's relevant for reni-cel, too. You know, first, what is your view on the feasibility and expected trajectory of building the necessary infrastructure to administer these gene therapies or gene-editing therapies? And second, what, if anything, can Editas do now to help prepare the market for when you potentially launch reni-cel commercially? Dude, thanks very much for that question, Samantha. What I'm going to do is actually ask our Chief Commercial Strategy Officer, Caren Deardorff, to answer that. Yes, thank you. Thanks, Sam, and just wanna add to Gilmore the congratulations to Bluebird and Vertex. It really is a great time in the field. So I look at this from two ways. One is definitely kind of the long-term perspective on having these life-transforming therapies available in a really critical population. And then there's also the short term of how do we get to a place where these patients have the access they need? And as you point out, you know, there are a number of considerations. What I'll say is there are definitely sites available today, but in my experience launching Spinraza, when we look at things like CAR T in general, when a drug is approved, a lot of work happens and starts then. So a lot of centers who anticipate and would like to get involved often can't build the infrastructure, hire the staff, you know, coordinate with their CFO and their C-suite to make sure it's possible. So I think that we will see that there is work to be done across the physician community, who we're hearing great things. But again, it will take a little bit of time across the payer community, which we also think will get there, but it will be slow. Government can work, you know, somewhat slowly, but between the government payer and the commercial payers, we believe that there is a huge cost savings and value proposition in these therapies. And then thirdly, the patient community and the education there. So I think that we will see maybe a slow start, but I think we will see eventually a very sizable opportunity and a way to get to these patients. In terms of what we can do, we're already engaged with the patient community through advocacy, doing a lot of listening, engaging, understanding what they need, and with sites, not just our own sites, but also other KOLs, to really understand what are some of the areas that they need support, or how are they gonna go ahead and build? So we are actively involved in those conversations. That will continue over the next years as we think about hopefully bringing reni-cel to the market. Thanks very much, Karen. Our next question comes from Yanan Zhu from Wells Fargo. Your line is open. Feel free to unmute. Hi, thanks for taking our questions, and congrats on the data. So I was wondering, in speaking about the greater, potentially greater total hemoglobin compared with exa-cel, as you mentioned, how much higher do you think, in the eyes of the sickle cell physicians, would equate to a clinically meaningful difference? Is it one gram per deciliter or two grams per deciliter? I think currently, the data suggest increment in that range. I just wonder about as you gather data and talk to treating physicians, what is the view that you're hearing? And I have a couple follow-up. Thanks. Thanks very much, Yanan. So I'm going to ask Baisong to answer that question. Yeah, thanks, Yanan, for the question. So, as I mentioned earlier, that the literature already demonstrate that increased hemoglobin level is very important for sickle cell patients. And so we are pleased to see that we'll be able to normalize hemoglobin. Then how much higher, I would say from like two angles. One is that just generally from hematology perspective, normal hemoglobin with anemia, that certainly will have different clinical outcome of that. And then from sickle cell specifically, they already are evident to say every gram of deciliter change will make a difference. There are several actually review article on that end, and also that the, if I pronounce the name, the Oxbryta, Oxbryta approval is based on the actually 1 gram of deciliter of total hemoglobin increase for the approval. So certainly that is a general consensus that normalized hemoglobin and also increase of 1 gram or more will be substantial. Thank you very much, Baisong. Thank you, Baisong and, Gilmore. That's very helpful. And then I see that, one patient had a, AE of polycythemia. Could you talk about that? Is that, associated with a particularly high, fetal hemoglobin expression, and, whether that's resolved? Thanks. Yeah. Thanks, thanks very much, Yanan. Baisong? Yeah, yeah. Happy to answer the question. So we do have one patient actually have slightly higher than normal range of total hemoglobin and transiently, and that has been seen to resolve quickly. Got it. Any understanding of, you know, the transience of this kind of reaction? Is that stem cells trying to, you know, repopulate the bone marrow niche and showing fluctuation, or I wasn't sure about the transient nature. Any thoughts there? Beisong- Yeah. I think we... Yeah, Gilmore. No, sorry, I was going to pass that. Just Andrew Baisong, if you, if you'd like to just address that. Obviously, as we... This was a, you know, a transient, single event, and the patient has remained with the normal. But Baisong, I think you were going to? Yeah, yeah. So this is a transient occurrence, and certainly we take this also very seriously. We have extensive investigation and also discussed with the IDMC. And then this patient has been resolved actually six months ago. So we actually have data for that, with patient on normalized for more than six, for six months. Got it. Very helpful. Thank you for taking the questions. Thanks very much, Yanan. Our next question comes from Luca Issi, from RBC Capital Markets. Oh, great. Can you guys hear me okay? Yes, thank you, Luca. Great. Terrific. Two quick questions. One, maybe circling back on prior questions on cell numbers. Can you just talk about what's the minimum number of CD34 positive hematopoietic stem cells that you need as a starting point to manufacture reni-cel? I found it interesting to learn on Friday that bluebird bio needs close to 20% less cells than actually CRISPR, according to their label, I believe 16.5 million cells for one or 20 million cells for the other. So I was just curious if your number is closer to bluebird bio's number or the CRISPR number, any color there, much appreciated. And then the second one, in a scenario where you actually get approved for both beta thalassemia and sickle cell disease, do you anticipate to receive one or two PRVs? Thanks so much. Thanks very much, Luca. With regard to question one, we haven't actually disclosed, you know, the starting number of cells that we are using right now. Baisong, I don't know if you just want to add, give clarity. Certainly we certainly have shared, you know, the range of cells that we administer. But Baisong, if you want to add any more to that. Yeah, yeah. So the dose of the reni-cel treatment is based on the experience had many years for allogeneic transplant. So that's gonna be generally used in this field. So we actually have a final minimum of 3 million cells per kilo for treatment of with edited cells. Yeah, yeah. But I think the other thing I just want to add, Luca, is that we are, you know, very happy with the efficiency of our enzyme. And one of the reasons that we actually chose to develop our program using AsCas12a is because, amongst other things, the high efficiency of this engineered enzyme. And we've been very happy to date with the efficiency of our editing. And then with regard to your second question, sorry, could you restate that for me? Happy to. Just curious about whether if you get approved for beta thalassemia and sickle cell disease, if you anticipate to receive one priority review voucher or two? Yeah. You know, frankly, that would be a matter of review with the FDA. Obviously, there's substantial upside if you get that. But yeah, and obviously, we have seen some interesting precedents set with the granting of a PRV for exa-cel. But I think we'll have much more clarity as we get closer to an approval. But really, it's a matter of review with the agency. Thank you. Happy. Thanks so much. Thanks very much. Our next question comes from Greg Harrison from Bank of America. Hi there, this is Mary Kate, on for Greg. Thanks for taking our questions and hosting the event today. Just a quick question on just how is enrollment going since the cutoff, for the data here? And then do you expect any impact on enrollment given the recent approvals in the space? Thank you. ... Thanks very much, Mary, for your question. I'll ask, Baisong, to answer the question on, on, you know, the continuing enrollment that we're seeing. And, and frankly, he, he can also comment on our belief that we do not expect to see an impact, on enrollment, indeed have not, seen it, with the approval. But Baisong, over to you. Yeah. Thank you. Thank you for the question. So we have a strong momentum for the clinical trial enrollment and the movement in that. And as we shared that in early January, the earnings call, we already had 27 patients enrolled at that time, but since we enrolled additional more patients on that too. We do not see any impact that about the approval of these two or the other that is, for example, approved last year. And we are still see very strong reaction from community, and we are still see a lot of interest from study sites and patients. What I would say is that the data, the more data we share, and we actually see a lot of positive response, right? So we, as a that since, for example, last June, after we released the data, our inquiry increased about tenfold over that period, right after that, the data sharing. So we expect that the data we have now, we're going to have even more positive results, results, reactions to the trials. Great. Thank you so much. Thanks very much. Thank you, Mary. Our next question comes from Phil Nadeau, from TD Cowen. Good afternoon, thanks for taking our question, and allow us to add our congratulations on the data. 2 from us. First, on the efficacy side, when could we first see some of that end organ function data that you mentioned? Do you think that you'll have that available in mid-2024, the next update, or will that require longer term follow-up? And then the second question, again, on differentiation. You've focused the differentiation on efficacy and efficacy measures. Talking to physicians, the safety profile of these agents is a big hurdle to adoption. Is there any way to differentiate on safety, or, since most of the adverse events are due to the preconditioning, is it difficult to differentiate meaningfully without changing the preconditioning regimen? Thank you. Thanks very much, Phil. I'm going to answer a question, too, and then pass question one to Baisong, you know, dealing with end organ functional data and the timing of such sharing. With regard to the safety profile, you know, obviously, we take safety extraordinarily seriously. Indeed, that was one of the reasons that we elected to move forward with the AsCas12a, which is not just a high efficiency enzyme, but actually is a higher fidelity CRISPR enzyme. And indeed, we felt that choice was further validated during the discussion at the AdCom, when we heard the agency's view of the importance of monitoring off-target editing. Indeed, at that agency AdCom, we actually also were very gratified to see how comprehensive our off-target editing package is relative to what the agency was discussing at the AdCom. And so we actually certainly do believe that, you know, that does give us another potential for differentiation with our product. Then with regard to end organ functional data, let me pass that to Baisong. Yeah. Thanks. Thanks for your question. Regarding the differentiation, we feel the end organ function can be an important point for differentiation, benefiting from the normalization of total hemoglobin and correction of anemia. As I mentioned before, there are actually reports that the normalization will help the patient and organ function wise. And then related to, you know, outcome and when and we'll be able to see the benefit, and this is actually still unknown area for us to explore. So they are relatively limited data on that, but there are publications about from allogeneic transplant for sickle cell patients, and they see the improvement of central nervous system, they see improvement in cardiovascular system. And actually, at least ASH, there are several abstracts talking about allogeneic transplant outcome. So we will together learn more about that. I cannot share a specific time frame, but we are monitoring this very closely and looking forward to share more data in the future. Thanks very much, Baisong. Thank you, Phil. Our next question comes from Eric Schmidt, from Cantor Fitzgerald. Eric, your line is open. Feel free to unmute. Awesome. Okay, we can come back to Eric. Let's go to take a question from Dae Gon Ha from Stifel. Hey, guys, thanks for taking our questions. Can you hear me okay? Yes. Thank you very much, Dae Gon Ha. Great. Great. Well, congrats on the progress, and the update today. Maybe, a quick clarification question before I dive into, my 2 questions. On the clarification part for the sickle cell data, can you confirm that the one with the 18-month follow-up is a male? And for the TDT dataset, for the N of 1 out to 8 months, what genotype was that particular patient? ... for that clarification, Gina, I'm gonna hand that to Baisong. Yeah, thanks. For the RUBY study, the patient with 18 months follow-up is a male patient. And for the EdiTH patient, those two patients with longer follow-up are also a male patient. I think, I think the question, Baisong, was around the genotype. Yeah, they actually are beta zero, beta plus. Okay. Okay, thank you for the clarification. For my actual questions, I guess with the Lyfgenia and the Casgevy approvals, I wanted to get your strategic take on this. Do you see the strategic rationale of activating or enlisting some of these Casgevy or Lyfgenia QTCs to kind of give these investigators early notion of differentiation of EDIT-301? Or will you be looking to, sort of skirt that and go after sites that are non-participating as QTCs? And then last question, we saw quite a bit of disparity on the pricing disclosure, $2.2 million for Casgevy, $3.1 million for Lyfgenia. I wanted to get your take on sort of the COGS, I guess, side of the calculus. How are you thinking about that as you're developing EDIT-301? How much of a wiggle room is there as you kinda see these two precedents that are coming to the market? Thanks so much. Thanks very much, Gina. You know, let me just answer the last question, and then I'll ask Karen just to begin to share her preliminary thinking about how, you know, how we think about qualified transplant center engagement, et cetera. So yes, you know, we did see that disparity or difference in pricing disclosure. It is very early days yet for us to be thinking about our pricing, and we have not shared our COGS yet, but would look forward to doing that at an appropriate time. And with that, Karen, I might ask you just to address, you know, share some of your thinking, preliminary thinking around how we're thinking around QTCs going forward, you know, as a how you say a rapid follower with a potentially differentiated product. No, thank you. Thank you for the question. Where I'll start is with the sites that we already have. We have about 25 sites that have really good distribution across the country, as well as utilizing some of the strongest thought leaders and centers who can do both the sickle cell care and the transplant care as well. So we already feel very good about our footprint. Starting there, I'm sure is quite a bit of overlap with the clinical trial sites for the other therapies and their QTCs. So I think, I think it's not necessarily about going after their QTCs. I think we all probably have a pretty similar strategy in looking at where the majority of patients are, how are they distributed across states, how are the, you know, Medicaid and the various payers going to move, how quickly will they move? And all of that we're taking into consideration. But again, starting with, gaining the experience through our NSF sites that we have in place today, and we'll continue to evaluate that, and I'm sure we'll update you as, as we go along. Thanks very much, Karen. And I'm worried that I think we have a few more people with questions, and it might be important just to make sure if we can try and focus the questions. Sorry about that. Sorry to be the bad man, bad guy. For our next question, we'll return to Eric Schmidt from Cantor Fitzgerald. Can you hear me now? Yes, Eric, we can hear you. We were worried. Okay, thank you. Thanks for giving me one more chance. Yeah, maybe quickly, just on this single case of grade 2 polycythemia vera, was there any medical intervention required? And then 2, I guess I'm just biologically very curious. It seems like 2 different things are going on in sickle cell versus beta thal, biologically. You're getting a lot more hemoglobin F production in beta thal than in sickle cell, yet the total hemoglobin is quite a bit lower or somewhat lower in beta thal versus sickle cell. Do we understand what's going on there biologically? Thank you. Thank you very much, Eric. And now, I ask Baisong just to, you know, you know, clarify on the single event of polycythemia, which was not a vera, which is a primary event, but Baisong, over to you. Yeah. Thanks, thanks, Eric, for that question. So, this patient had a transient higher total hemoglobin level of during this visit. And it... The major intervention was that at the time, actually, the patient, because the patient had a big pulmonary embolism thrombosis before, so the physician feel that even though the level was not very high, but did a phlebotomy to reduce the total hemoglobin level. And the way important thing, of course, is the nuance of patient management, is that this patient was considered, even though they have high total hemoglobin level, and this patient is considered actually iron deficiency. So keyword before this event was put iron supplement before this event. And then after the stop, the iron supplement, and this patient has since been have normal total hemoglobin levels for the past six months. Thanks very much, Baisong. And then I think, Eric, you asked a question around the relative levels or expression of fetal hemoglobin in the context of sickle cell disease versus beta thalassemia. And I think, you know, while it's always dangerous to speculate, there is no doubt that these diseases are different biologically. And obviously, as we move this medicine forward and it interacts with the biologies of these different patients, we will gain additional insights. Baisong, I don't have anything to add to that. Yeah, yeah. I do want to add a couple of things in here, right? So one is that the patients with five months follow-up has really robust total hemoglobin level around 13 grams per deciliter, well above the transfusion dependence, and it's very conclusive results. And two is that a transfusion-dependent beta thalassemia is different from sickle cell, actually, because this transfusion-dependent thalassemia, they have very low total hemoglobin level. It's like below seven grams per deciliter. So they have the difference from pathophysiology perspective. And as I mentioned earlier, we are very happy with the data, and we're looking forward to more data come from longer follow-up and more patients. Thanks very much, Baisong. Thanks, Eric. Our next question comes from Brian Cheng from JP Morgan. Brian, your line is open. Feel free to unmute. Hey, guys, can you hear me now? Yes, Brian, we can hear you. Thank you. Hey, yeah. Hey, good morning. Thanks for taking my question, and, congrats on the progress. Can you walk us through how the patient journey is to get on reni-cel, and I guess whether there is any key difference versus exa-cel today? And what is the current vein to vein time as you now have a handful of patients in both trials? And I guess as you look forward to next year, how do you think that vein to vein time will improve over time? Thanks very much, Brian. Let me start very quickly before handing to Karen, as we were thinking about the evolution of our patient journey and how that will translate from our clinical trial experience to the commercial space. You know, with regard to the vein to vein time, certainly the sickle cell patient, our experience has been, as we've shared before, about five to 12 months, and not surprisingly, it's so it can be shorter with beta thalassemia patients, largely because you can use double agents to mobilize them and therefore get higher yields in the apheresis. With that, I might ask Karen just if she'd like to comment on just the evolution of her or her preliminary thinking about what that journey will look like in the future and how we're thinking about that. Yeah. Thanks, Brian. I'm actually going to be very quick and then have Baisong comment more on from a clinical trial perspective. I'd say there is a somewhat artificial path within the clinical trial where there are more steps. So I would anticipate what we do today will translate, but we'll be able to find places to optimize. But Baisong, do you want to comment just on the steps and- Yeah, yeah. I mean, I think, Brian, you're very familiar with this. So we actually have this, you know, after eligibility, we have these, apheresis, collect cells and manufacture cells, and then dosing. And then the one of the major factor is, for example, the patient conditioning, because those are severe sickle cell patients, and before they had, reni-cel treatment, they could have all kinds of different safety, and adverse event before the treatment because they are severe patients. So that's kind of one part of that. And the other part is actually patient scheduling, because this is a very, very, involving study and require not only patient commitment, but a caregiver's commitment. So as Gilmore mentioned, we actually do see room to optimize it, but certainly there are... This is because the nature of severe disease, the devastating disease we're in. And Brian, just the final thing is that we have actually evolved our processes and brought in best practices as we move the trial forward, and, you know, look forward to talking about more of that in the future, appropriate time, and seeing how and describing how it will ultimately impact the commercial journey for patients using reni-cel. Great. Thanks, guys. Thank you. Thank you. Thanks very much, Brian. Our next question comes from Jay Olson from Oppenheimer. Your line is open. Feel free to unmute. Oh, hey, congrats on these results, and thank you for the update. Can you comment on the opportunity to treat younger sickle cell patients with reni-cel? And separately, are you collecting any biomarkers for hemolysis, like LDH? Thank you. Yes, thanks very much, Jay. What I'm going to do is ask Baisong to talk about how we're moving on the treatment of younger patients, and I can confirm that we are collecting markers of hemolysis, and Baisong could probably talk a little about, you know, at a high level, as we shared at the ASH poster, about where we're seeing a very positive trends there. Baisong, over to you with regard to the opportunity to treat younger patients. Yeah, yeah, yeah. Thanks, Jay. We certainly have a plan for expanding this study to the younger patient, and we will expand it to adolescent patient first before we go to under 12 pediatric patients. So we are well on the way for that, and that's our plan. And then in terms of the hemolysis marker, we certainly collect the LDH and reticulocytes, as you mentioned by that, and we're very happy to see the data we have seen so far. I mean, our data set is still small, but we're very happy to see, as we put in the poster, that those parameters either normalize or have a significant improvement. So we're very happy to see the data we've collected so far. Thanks very much, Jay.... Thank you. Our final question will come from Jingming Chen from Evercore. Hi, can you guys hear me? Yes, we can. Oh, great. Hi. Yeah. Hi, this is Jingming, also for Liisa. Thanks for taking our question. So we're just curious, we know fetal hemoglobin binds to oxygen better than the regular hemoglobin. So do you really think, we need, you know, normal level of total hemoglobin to have normal functions? Thank you. Thanks very much for your question. I'm going to ask Baisong Mei to address that. In many ways, we've partially addressed that with some of the empirical observations seen in with hereditary persistence and even, indeed, in our own experience in the clinic to date. But Baisong Mei? Yeah. Thanks for the question. So, actually, there are probably two aspect of that, right? So one is to say, look, to prevent sickling in the sickle cell patients, you do need certain level of that, whether it's the higher, the better, and how much we need, that's kind of one topic of that. And then the other one is actually, yes, the fetal hemoglobin has high affinity to oxygen and then the adult hemoglobin, and then what level is necessary. So based on our data, of course, other data, other people's study data, that higher level of total hemoglobin or high percentage of fetal hemoglobin, since the patient been doing very well. So there's no concern to have a higher fetal hemoglobin, per se. and so that's kind of how the knowledge we have so far. It's not only for these trials, but also for the hereditary persistence of fetal hemoglobin patients demonstrate that in the beta thalassemia patients. And it is worth pointing out that the question is, you know, quite apt considering the relative affinities of fetal hemoglobin and adult hemoglobin. But it's worth noting that the affinity of oxygen for hemoglobin is also modified by adaptive mechanisms, including, you know, 2,3-DPG, pH, oxygen tensions, et cetera, in the tissues. But the good thing is that we are seeing essentially very good outcomes in our experience and the hereditary persistence of fetal hemoglobin experience, you know, particularly where you're looking at it in the co-inherited with thalassemia, where fetal hemoglobin is dominant. These patients are doing very well, or I shouldn't say patients, these people with that coincident inheritance do very well. Got it. Thank you. Thank you very much. So I think that was our last question. So I, I just want to thank all of you for your interest in dialing in. We are very excited by the data we were able to share with you. We're happy with the momentum, and we look forward to giving you further updates and obviously look forward to you know being able to share a substantial data set in the middle of next year. Take care. Ladies and gentlemen, this concludes today's call. Thank you once again for your participation. You may now disconnect.